IL2 and systemic lupus erythematosus: There is consistency among reports that low-dose IL-2 therapy is well tolerated and associates with the expansion of Tregs (also in conditions different from SLE, as shown in a multi-center clinical basket trial with forty-six patients with multiple diseases that included six SLE patients).[53] However, the expansion of Tregs appears not to be the only factor affected by therapy with low-dose IL-2.